Immune Pharmaceuticals has announced that Boris Shor, Ph.D. has joined the company as Executive Director, R&D and Scientific Partnerships.
Dr. Shor will be establishing and directing a new immunology research laboratory at the Alexandria Center for Life Science in New York City for Immune, at the company's headquarters. He will lead translational research efforts to support the development of the company's lead clinical stage candidate, bertilimumab, as well as the discovery and development of pipeline drugs utilizing NanomAbs®, antibody nano-conjugates for the targeted delivery of cancer drugs.
Dr. Shor commented: "I am delighted to join Immune at this important time as bertilimumab is advancing through the clinic and other exciting programs are coming on-line. The strength of science across immunology and oncology programs at Immune is impressive." Dr. Shor continued, "I also see potential for Immune's nanotechnology delivery platform for the effective treatment of diverse diseases including cancer. This provides a remarkable opportunity to play a major role in building an organization that is improving lives and outcomes in patients with autoimmune diseases and cancer."
Dr. Shor brings more than a decade of pharma industry experience in oncology drug discovery, early development and translational research, with expertise in both biologics and small molecule therapeutics. He joins Immune from the Pfizer Oncology Research Unit where he led internal and external collaboration project teams to develop novel antibody-drug conjugates (ADCs) for the treatment of cancer. Most recently, Dr. Shor was also responsible for authoring regulatory documents including the non-clinical pharmacology section for the Biological License Application (BLA) of a late stage ADC. Dr. Shor received a Ph.D. in Molecular and Cell Biology at the State University of New York and performed a postdoctoral fellowship in the Inflammation Research team at Johnson & Johnson Pharmaceutical R&D prior to joining Pfizer.